Jorn Aldag
Chairman
management
Molecular Partners
Switzerland
Biography
Jorn Aldag is Chairman of the Board of Directors of Molecular Partners Ltd. From 2009 to the end of 2015 he was CEO of the gene therapy company uniQure N.V., the Netherlands, which received the first approval of a gene therapy product by any Western regulatory agency and was recently listed on NASDAQ (QURE). From 1997 to 2000 Mr. Aldag was President & CFO of Evotec AG. From 2000 to 2008 he was President & CEO of Evotec AG. During his tenure at Evotec AG, he transformed the company from being a provider of ultra-high throughput screening equipment to a leading clinical research organization with a proprietary pipeline of drug programs for the Central Nervous System, listed the company at the Frankfurt Stock Exchange and at NASDAQ, and managed the acquisition of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. Mr. Aldag holds business degrees from the European Business School and the Harvard Business School.
Research Interest
business and management finance
